South Asian Journal of Engineering and Technology Research Article

Open Access Full Text Article 152(2025) 10-20 DOI: 10.26524/sajet.2023.15.3

Exploring the Role of Gut Microbiota in Antibiotic Resistance Reservoirs

Dimple M.D, Nirmala Devi*

Post Graduate Department of Microbiology. Maharani's Science College For Women (Autonomous), Mysuru, Karnataka 570005

Corresponding author.
Correspondence: Nirmala Devi
E-mail: nirmaladevi1012@gmail.com

Article info
Received 15th October 2024
Revised form 10th December 2024
Accepted 2nd February 2025

Keywords
Client experience/fulfilment, CCRF, cost, planning

https://sajet.in/index.php/journal/article/view/307

Abstract
Antimicrobial resistance (AMR) presents a growing global health crisis, complicating the treatment of common infections and leading to increased morbidity, mortality, and healthcare costs. While the overuse and misuse of antibiotics in human medicine and agriculture have been identified as primary drivers of AMR, the role of the human gut microbiota as a reservoir for resistant bacteria has gained increasing attention. The gut microbiota, a complex community of microorganisms, plays a crucial role in maintaining health but can act as a breeding ground for antibiotic-resistant pathogens when disrupted by antibiotic use. This disruption leads to dysbiosis, fostering the growth of resistant bacteria, which can harbor and share resistance genes, further perpetuating AMR. Additionally, horizontal gene transfer within the gut microbiota allows resistant traits to spread across different bacterial species, compounding the problem. This paper explores the mechanisms through which the gut microbiota contributes to the development and transmission of AMR, emphasizing the role of antibiotics in altering microbial composition. Furthermore, it highlights potential strategies for mitigating AMR, including microbiota-modulating therapies such as probiotics and prebiotics, fecal microbiota transplantation, and alternative treatments like bacteriophage therapy. The paper concludes by advocating for a multifaceted approach to combat AMR, with a focus on preserving gut microbiota health and implementing stricter antibiotic stewardship practices.

INTRODUCTION

Antimicrobial resistance (AMR) has become one of the most significant global health threats in recent decades, undermining the efficacy of many antibiotics that have long been the cornerstone of medical practice [1]. AMR occurs when microorganisms, such as bacteria, viruses, fungi, and parasites, evolve mechanisms that render them resistant to the drugs used to treat infections they cause [2]. This phenomenon is particularly alarming as it leads to infections that are harder to treat, longer in duration,

and more costly, significantly increasing morbidity and mortality rates. While the primary drivers of AMR have traditionally been the overuse and misuse of antibiotics in both human healthcare and agriculture, a growing body of evidence now points to the gut microbiota as a critical player in the development, dissemination, and persistence of antibiotic-resistant bacteria [3].

The gut microbiota is a vast and diverse community of microorganisms that live in the digestive tract. It plays an essential role in human health by aiding digestion, synthesizing vitamins, and modulating the immune system [4]. However, the use of antibiotics, particularly broad-spectrum ones, can disrupt the natural balance of these microbes, leading to dysbiosis, a condition where the beneficial microbes are reduced and resistant bacteria thrive [5]. As these resistant microbes proliferate, they can harbor and transmit antibiotic resistance genes, posing a significant challenge to public health [6].

The gut microbiota not only acts as a reservoir for these resistant organisms but also facilitates the transfer of resistance genes through mechanisms such as horizontal gene transfer. This process allows bacteria to share their resistance traits with other bacteria, further exacerbating the spread of AMR [2]. This dynamic interplay between antibiotics, the gut microbiota, and antibiotic-resistant bacteria underscores the importance of studying the gut as a key reservoir for AMR. In this paper, we will explore the mechanisms through which the gut microbiota contributes to antibiotic resistance and discuss the broader implications for human health and the global fight against AMR [7].

Understanding how antibiotic resistance evolves within the gut and spreads to other parts of the body is crucial for developing effective strategies to combat AMR. By exploring the relationship between the gut microbiota and antibiotic resistance, this paper aims to provide a comprehensive overview of the factors that influence the development and transmission of AMR, along with potential interventions to mitigate its impact. The findings from this exploration will help inform future research and public health initiatives aimed at preserving the effectiveness of antibiotics and reducing the burden of antibiotic-resistant infections.

2. THE GUT MICROBIOTA: COMPOSITION AND FUNCTION

The human gut microbiota is a complex ecosystem made up of trillions of microorganisms, including bacteria, viruses, fungi, and archaea, that reside in the gastrointestinal tract. It plays a vital role in various physiological processes, including digestion, immune system regulation, and metabolism [8]. The composition of the gut microbiota varies significantly among individuals but is generally dominated by two main bacterial phyla, Firmicutes and Bacteroidetes. These microorganisms help break down complex carbohydrates, synthesize essential vitamins, and protect against harmful pathogens by outcompeting them for nutrients and space [9]. The gut microbiota also interacts with the immune system, influencing both innate and adaptive immunity. Under normal conditions, there is a dynamic balance between beneficial microbes (such as Lactobacilli and Bifidobacteria) and pathogenic

microorganisms. However, factors like diet, stress, and especially the use of antibiotics can disrupt this balance, leading to dysbiosis, or an imbalance in the microbial community [10]. Dysbiosis often results in the overgrowth of pathogenic bacteria, including those that harbor antibiotic resistance genes, increasing the risk of infections and complicating treatment. This section highlights the functions of the gut microbiota, emphasizing its role in maintaining health and how antibiotics can disrupt this delicate balance [11].

3. MECHANISMS OF ANTIBIOTIC RESISTANCE IN THE GUT MICROBIOTA

The gut microbiota plays a pivotal role in the development and spread of antibiotic resistance. Bacteria within the gut can acquire resistance to antibiotics through several mechanisms, including mutations, horizontal gene transfer (HGT), and the formation of biofilms. Mutations in bacterial DNA can lead to alterations that confer resistance to specific antibiotics, making them less effective. Horizontal gene transfer is a key mechanism through which resistance genes spread among bacteria [12]. This process allows bacteria to transfer genetic material, including antibiotic resistance genes, to other bacteria, even across species. Mobile genetic elements, such as plasmids, transposons, and integrons, are particularly important in facilitating HGT [13]. These elements can carry multiple resistance genes and enable bacteria to acquire resistance rapidly, even to previously effective antibiotics. Biofilm formation is another critical factor in resistance, as biofilms protect bacteria from the action of antibiotics and the immune system, allowing for prolonged survival [14]. These mechanisms are facilitated by the diverse and dense microbial environment within the gut, making it an ideal setting for the selection and propagation of resistant bacteria. This section explores these mechanisms, providing insights into how bacteria in the gut develop and disseminate resistance to antibiotics [11].

4. IMPACT OF ANTIBIOTIC USE ON THE GUT MICROBIOTA

The use of antibiotics has a profound impact on the gut microbiota, often leading to the disruption of its normal balance. Antibiotics, particularly broad-spectrum ones, do not only target pathogenic bacteria but also affect beneficial microorganisms [11]. This can lead to a reduction in microbial diversity, known as dysbiosis, which increases the susceptibility to infections and promotes the growth of resistant bacteria. Antibiotics induce changes in the microbial composition, often leading to the overgrowth of opportunistic pathogens such as Clostridium difficile, which can cause severe gastrointestinal infections [15]. Moreover, the prolonged or repeated use of antibiotics further exacerbates dysbiosis, making the microbiota more prone to harboring antibiotic-resistant bacteria. This selective pressure from antibiotics favors the survival of resistant organisms, allowing them to proliferate and colonize the gut [11]. These resistant bacteria can then become reservoirs for resistance genes, which can be transferred to other bacteria through horizontal gene transfer. The disturbance of the gut microbiota can also weaken the body's immune defenses, reducing the effectiveness of the

body's natural ability to fight off infections. This section examines the impact of antibiotic use on the microbiota, focusing on how such disruptions contribute to the rise of AMR [15].

5. THE ROLE OF THE GUT MICROBIOTA IN THE TRANSMISSION OF AMR TO HUMANS

The gut microbiota acts as a reservoir for antibiotic-resistant bacteria, which can be transmitted to humans in various ways. One of the primary routes of transmission is through the consumption of contaminated food. Resistant bacteria can be present in animal products such as meat, milk, and eggs, particularly when antibiotics are used in livestock farming [16]. Upon ingestion, these bacteria can colonize the human gut, potentially causing infections that are difficult to treat. Additionally, resistant bacteria can be transmitted through direct contact with animals or other individuals, particularly in healthcare settings or environments with poor hygiene practices [17]. Furthermore, resistant pathogens can translocate from the gut to other parts of the body, where they can cause systemic infections. The spread of resistant bacteria can also occur through the environmental pathway, with resistant bacteria being excreted in feces, contaminating water sources, soil, and agricultural fields [18]. The environmental contamination facilitates the dissemination of resistant organisms to humans through indirect contact. This section delves into how resistant bacteria from the gut are transmitted to humans and the potential consequences for public health. It also explores the broader impact of the gut microbiota as a conduit for AMR [19].

6. CLINICAL IMPLICATIONS OF GUT MICROBIOTA IN AMR

The emergence of antibiotic-resistant bacteria in the gut microbiota has serious clinical implications. When resistant pathogens enter the bloodstream or other sterile areas, they can cause infections that are difficult to treat, leading to longer hospital stays, increased healthcare costs, and a higher mortality rate [20]. The gut microbiota's role in the persistence of resistant bacteria complicates the management of infections, particularly when infections arise from the gut. Infections caused by resistant bacteria often require the use of more potent, last-resort antibiotics, which may have higher toxicity levels or limited availability [21]. Moreover, treating infections that have originated from the gut can result in prolonged antimicrobial therapy, which further disturbs the microbial balance. As resistant bacteria can spread easily within the hospital setting, infections caused by AMR can lead to healthcare-associated outbreaks [11]. The presence of resistant bacteria in the gut also complicates the use of traditional antibiotics, as clinicians may be forced to choose treatments that are less effective or more costly [22]. This section explores the clinical challenges posed by AMR, highlighting the difficulties in managing resistant infections and the importance of strategies such as antibiotic stewardship and targeted therapies.

7. STRATEGIES FOR MODULATING THE GUT MICROBIOTA TO COMBAT AMR

Given the central role of the gut microbiota in the development and transmission of AMR, strategies aimed at modulating the microbiota and Nnaotechnologies offer promising avenues for combating resistance [23][24][25]. One approach is to restore the balance of the gut microbiota after antibiotic use by promoting the growth of beneficial bacteria through dietary changes, prebiotics, and probiotics [11]. These interventions aim to re-establish a healthy microbial community, which can outcompete resistant pathogens and reduce the risk of infections. Fecal microbiota transplantation (FMT) has also shown promise as a therapeutic option, as it involves transferring healthy microbiota from a donor to a patient's gut to restore microbial balance and eliminate resistant bacteria [26]. In addition to microbiota-modulating therapies, the development of alternatives to antibiotics, such as bacteriophage therapy, antimicrobial peptides, and vaccines, can help reduce the reliance on antibiotics for infection treatment and prevention. Vaccines targeting common pathogens, including those harboring resistance genes, can prevent infections and reduce the spread of AMR [27]. This section reviews these strategies, highlighting the potential benefits and challenges associated with modulating the gut microbiota to combat AMR.

8. CONCLUSION

The gut microbiota plays an integral role in the development and spread of antimicrobial resistance (AMR), acting as a key reservoir for resistant bacteria and facilitating the transfer of resistance genes. The use of antibiotics, particularly broad-spectrum ones, significantly alters the balance of the gut microbiota, promoting the survival of resistant pathogens. This disruption, known as dysbiosis, increases the prevalence of antibiotic-resistant bacteria in the gut, which can spread to other parts of the body, leading to more difficult-to-treat infections. Additionally, the process of horizontal gene transfer within the microbiota enables bacteria to share their resistance traits, amplifying the scope of AMR across species and environments.

To address the growing AMR crisis, it is essential to consider strategies that focus on maintaining or restoring the health of the gut microbiota. Interventions such as probiotics, prebiotics, and fecal microbiota transplantation (FMT) offer promising approaches to modulating the microbiome and reducing the prevalence of resistant organisms. The development of alternative therapies, such as bacteriophage therapy and antimicrobial peptides, could provide additional tools to combat infections without relying solely on antibiotics.

Furthermore, AMR requires a multifaceted approach, including stricter regulations on antibiotic use in both human healthcare and agriculture, along with improved hygiene and infection control practices. Educating the public and healthcare providers on the importance of responsible antibiotic use and its impact on the microbiota is also critical. Continued research into the complex interplay between

antibiotics, the gut microbiota, and AMR is essential for developing new strategies to prevent and mitigate the spread of resistance.

In conclusion, combating AMR is not solely about developing new antibiotics but also involves preserving the natural balance of the microbiota and reducing the selective pressures that contribute to resistance. By adopting a holistic approach that includes microbiota-targeted therapies, antibiotic stewardship, and alternative treatment strategies, we can help mitigate the impact of AMR and ensure the continued effectiveness of antibiotics in treating infections. The future of public health depends on our ability to protect the microbiota, manage antibiotic use responsibly, and implement comprehensive strategies to curb the rise of antimicrobial resistance.

Acknowledgement

Nill

Funding

No funding was received to carry out this study.

REFERENCES

1. BAKER, S., NIRANJAN, RAJ. S., MANJU, K., RANJINI, H. K., & SHAYISTA, H. (2023). EFFICACY OF BREAST MILK COMPONENTS AGAINST MICROBIAL PATHOGENS TO COMBAT DRUG-RESISTANCE. THE MICROBE, 1, 100010. HTTPS://DOI.ORG/10.1016/J.MICROB.2023.100010
2. RUSSO, T. P., MINICHINO, A., GARGIULO, A. R., VARRIALE, L., BORRELLI, L., PACE, A., SANTANIELLO, A., POMPAMEO, M., FIORETTI, V., & DIPINETO, L. (2022). PREVALENCE AND PHENOTYPIC ANTIMICROBIAL RESISTANCE AMONG ESKAPE BACTERIA AND ENTEROBACTERALES STRAINS IN WILD BIRDS. ANTIBIOTICS, 11(12), 1825. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS11121825
3. LIO, R. M. S., FAVARA, G., MAUGERI, A., BARCHITTA, M., & AGODI, A. (2023). HOW ANTIMICROBIAL RESISTANCE IS LINKED TO CLIMATE CHANGE: AN OVERVIEW OF TWO INTERTWINED GLOBAL CHALLENGES. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 20(3), 1681. MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE. HTTPS://DOI.ORG/10.3390/IJERPH20031681
4. SHAYISTA, H., PRASAD, M. N. N., RAJ, S. N., PRASAD, A., LAKSHMI, S., RANJINI, H. K., MANJU, K., RAVIKUMARA, CHOUHAN, R. S., KHOHLOVA, O. Y.,

ПЕРЬЯНОВА, O. B., & BAKER, S. (2024). COMPLEXITY OF ANTIBIOTIC RESISTANCE AND ITS IMPACT ON GUT MICROBIOTA DYNAMICS. ENGINEERING MICROBIOLOGY, 100187. HTTPS://DOI.ORG/10.1016/J.ENGMIC.2024.100187

5. BAKER, S., PERIANOVA, O. V., PRUDNIKOVA, S. V., KUZMIN, A., POTKINA, N. K., KHOHLOVA, O. Y., & LOBOVA, T. I. (2020). PHYTOGENIC NANOPARTICLES TO COMBAT MULTI DRUG RESISTANT PATHOGENS AND PHOTOCATALYTIC DEGRADATION OF DYES. BIONANOSCIENCE, 10(2), 486-492.
6. TSIGALOU, C., KONSTANTINIDIS, T., STAVROPOULOU, E., BEZIRTZOGLOU, E., & TSAKRIS, A. (2020). POTENTIAL ELIMINATION OF HUMAN GUT RESISTOME BY EXPLOITING THE BENEFITS OF FUNCTIONAL FOODS. FRONTIERS IN MICROBIOLOGY, 11. FRONTIERS MEDIA. HTTPS://DOI.ORG/10.3389/FMICB.2020.00050
7. RUSSO, T. P., MINICHINO, A., GARGIULO, A. R., VARRIALE, L., BORRELLI, L., PACE, A., SANTANIELLO, A., POMPAMEO, M., FIORETTI, V., & DIPINETO, L. (2022). PREVALENCE AND PHENOTYPIC ANTIMICROBIAL RESISTANCE AMONG ESKAPE BACTERIA AND ENTEROBACTERALES STRAINS IN WILD BIRDS. ANTIBIOTICS, 11(12), 1825. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS11121825
8. ANTHONY, W., BURNHAM, C. D., DANTAS, G., & KWON, J. H. (2020). THE GUT MICROBIOME AS A RESERVOIR FOR ANTIMICROBIAL RESISTANCE. THE JOURNAL OF INFECTIOUS DISEASES, 223. OXFORD UNIVERSITY PRESS. HTTPS://DOI.ORG/10.1093/INFDIS/JIAA497
9. SHAYISTA, H., PRASAD, M. N. N., RAJ, S. N., RANJINI, H. K., MANJU, K., & BAKER, S. (2024). MECHANISTIC OVERVIEW OF GUT MICROBIOTA AND MUCOSAL PATHOGENS WITH RESPECT TO CARDIOVASCULAR DISEASES. THE MICROBE, 5, 100160. HTTPS://DOI.ORG/10.1016/J.MICROB.2024.100160
10. VINCENZO, F. D., GAUDIO, A. D., PETITO, V., LOPETUSO, L. R., & SCALDAFERRI, F. (2023). GUT MICROBIOTA, INTESTINAL PERMEABILITY, AND SYSTEMIC INFLAMMATION: A NARRATIVE REVIEW . INTERNAL AND EMERGENCY MEDICINE, 19(2), 275. SPRINGER SCIENCE+BUSINESS MEDIA. HTTPS://DOI.ORG/10.1007/S11739-023-03374-W
11. CRISTOFORI, F., DARGENIO, V. N., DARGENIO, C., MINIELLO, V. L., BARONE, M., & FRANCAVILLA, R. (2021). ANTI-INFLAMMATORY AND

IMMUNOMODULATORY EFFECTS OF PROBIOTICS IN GUT INFLAMMATION: A DOOR TO THE BODY. FRONTIERS IN IMMUNOLOGY, 12. FRONTIERS MEDIA. HTTPS://DOI.ORG/10.3389/FIMMU.2021.578386

12. CUSUMANO, G., FLORES, G. A., VENANZONI, R., & ANGELINI, P. (2025). THE IMPACT OF ANTIBIOTIC THERAPY ON INTESTINAL MICROBIOTA: DYSBIOSIS, ANTIBIOTIC RESISTANCE, AND RESTORATION STRATEGIES. ANTIBIOTICS, 14(4), 371. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14040371
13. DONG, J., RUSSO, J. D., & SAMPSON, K. Y. (2020). POPULATION DYNAMICS MODEL AND ANALYSIS FOR BACTERIA TRANSFORMATION AND CONJUGATION. JOURNAL OF PHYSICS COMMUNICATIONS, 4(9), 95021. HTTPS://DOI.ORG/10.1088/2399-6528/ABB8BE
14. GUO, Y. (2021). REMOVAL ABILITY OF ANTIBIOTIC RESISTANT BACTERIA (ARB) AND ANTIBIOTIC RESISTANCE GENES (ARGS) BY MEMBRANE FILTRATION PROCESS. IOP CONFERENCE SERIES EARTH AND ENVIRONMENTAL SCIENCE, 801(1), 12004. HTTPS://DOI.ORG/10.1088/1755-1315/801/1/012004
15. VARELA, M. F., STEPHEN, J., LEKSHMI, M., OJHA, M., WENZEL, N., SANFORD, L. M., HERNANDEZ, A. J., PARVATHI, A., & KUMAR, S. (2021). BACTERIAL RESISTANCE TO ANTIMICROBIAL AGENTS . ANTIBIOTICS, 10(5), 593. MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS10050593
16. CUSUMANO, G., FLORES, G. A., VENANZONI, R., & ANGELINI, P. (2025). THE IMPACT OF ANTIBIOTIC THERAPY ON INTESTINAL MICROBIOTA: DYSBIOSIS, ANTIBIOTIC RESISTANCE, AND RESTORATION STRATEGIES. ANTIBIOTICS, 14(4), 371. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14040371
17. CUSUMANO, G., FLORES, G. A., VENANZONI, R., & ANGELINI, P. (2025). THE IMPACT OF ANTIBIOTIC THERAPY ON INTESTINAL MICROBIOTA: DYSBIOSIS, ANTIBIOTIC RESISTANCE, AND RESTORATION STRATEGIES. ANTIBIOTICS, 14(4), 371. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14040371
18. RAMÍREZ, J. A., GUARNER, F., FERNANDEZ, L. B., MARUY, A., SDEPANIAN, V. L., & COHEN, H. (2020). ANTIBIOTICS AS MAJOR DISRUPTORS OF GUT MICROBIOTA . FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 10. FRONTIERS MEDIA. HTTPS://DOI.ORG/10.3389/FCIMB.2020.572912
19. CUSUMANO, G., FLORES, G. A., VENANZONI, R., & ANGELINI, P. (2025). THE IMPACT OF ANTIBIOTIC THERAPY ON INTESTINAL MICROBIOTA: DYSBIOSIS,

ANTIBIOTIC RESISTANCE, AND RESTORATION STRATEGIES. ANTIBIOTICS, 14(4), 371. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14040371

20. RAMÍREZ, J. A., GUARNER, F., FERNANDEZ, L. B., MARUY, A., SDEPANIAN, V. L., & COHEN, H. (2020). ANTIBIOTICS AS MAJOR DISRUPTORS OF GUT MICROBIOTA . FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 10. FRONTIERS MEDIA. HTTPS://DOI.ORG/10.3389/FCIMB.2020.572912
21. ROSSI, C. C., PEREIRA, M. F., & GIAMBIAGI-DEMARVAL, M. (2020). UNDERRATED STAPHYLOCOCCUS SPECIES AND THEIR ROLE IN ANTIMICROBIAL RESISTANCE SPREADING. GENETICS AND MOLECULAR BIOLOGY, 43. HTTPS://DOI.ORG/10.1590/1678-4685-GMB-2019-0065
22. RAHMAN, MD. M., DEVNATH, P., RAFSHAN, J., & TALUKDER, A. (2021). DETECTION OF MULTIPLE ANTIBIOTIC-RESISTANT BACTERIA FROM THE HOSPITAL AND NON-HOSPITAL WASTEWATER SOURCES OF A SMALL TOWN IN NOAKHALI, BANGLADESH. JOURNAL OF APPLIED BIOLOGY & BIOTECHNOLOGY. HTTPS://DOI.ORG/10.7324/JABB.2021.9308
23. SIĞIRCI, B. D., ÇELIK, B., HALAÇ, B., KAHRAMAN, B. B., BAĞCIGİL, A. F., & AK, S. (2021). CHARACTERIZATION OF FAECAL ENTEROCOCCI FROM WILD BIRDS IN TURKEY AND ITS IMPORTANCE IN ANTIMICROBIAL RESISTANCE. JOURNAL OF THE HELLENIC VETERINARY MEDICAL SOCIETY, 72(3), 3015. HTTPS://DOI.ORG/10.12681/JHVMS.28482
24. CRITS-CHRISTOPH, A., HALLOWELL, H., KOUTOUVALIS, K., & SUEZ, J. (2022). GOOD MICROBES, BAD GENES? THE DISSEMINATION OF ANTIMICROBIAL RESISTANCE IN THE HUMAN MICROBIOME [REVIEW OF GOOD MICROBES, BAD GENES? THE DISSEMINATION OF ANTIMICROBIAL RESISTANCE IN THE HUMAN MICROBIOME]. GUT MICROBES, 14(1). LANDES BIOSCIENCE. HTTPS://DOI.ORG/10.1080/19490976.2022.2055944
25. KORCZAK, L., MAJEWSKI, P., IWANIUK, D., SACHA, P., MATULEWICZ, M., WIECZOREK, P., MAJEWSKA, P., WIECZOREK, A., RADZIWON, P., & TRYNISZEWSKA, E. (2024). MOLECULAR MECHANISMS OF TIGECYCLINE-RESISTANCE AMONG ENTEROBACTERALES. FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 14. HTTPS://DOI.ORG/10.3389/FCIMB.2024.1289396
26. NWOBODO, D. C., UGWU, M., ANIE, C. O., AL-OUQAILI, M. T. S., IKEM, J. C., CHIGOZIE, V. U., & SAKI, M. (2022). ANTIBIOTIC RESISTANCE: THE CHALLENGES AND SOME EMERGING STRATEGIES FOR TACKLING A GLOBAL

MENACE. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 36(9). WILEY. HTTPS://DOI.ORG/10.1002/JCLA.24655

27. CUSUMANO, G., FLORES, G. A., VENANZONI, R., & ANGELINI, P. (2025). THE IMPACT OF ANTIBIOTIC THERAPY ON INTESTINAL MICROBIOTA: DYSBIOSIS, ANTIBIOTIC RESISTANCE, AND RESTORATION STRATEGIES. ANTIBIOTICS, 14(4), 371. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14040371\
28. SHAYISTA, H., PRASAD, M. N. N., RAJ, S. N., PRASAD, A., SATISH, S., RANJINI, H. K., MANJU, K., RAVIKUMARA, CHOUHAN, R. S., KHOHLOVA, O. Y., ПЕРЬЯНОВА, O. B., LAKSHMI, S., & BAKER, S. (2025). IMPACT OF MACROLIDE ANTIBIOTICS ON GUT MICROBIOTA DIVERSITY WITH AGE-SPECIFIC IMPLICATIONS AND SCIENTIFIC INSIGHTS. MEDICINE IN MICROECOLOGY, 100122. HTTPS://DOI.ORG/10.1016/J.MEDMIC.2025.100122
29. SYED, B., PRUDNIKOVA, S. V., PERIANOVA, O. V., ZHARKOV, S. M., KUZMIN, A., CHOUHAN, R. S., ... & SINGH, M. (2019). PHYTOGENIC SYNTHESIS OF AG BIONANO-ANTIBIOTICS AGAINST ESKAPE DRUG RESISTANT COMMUNITIES IN KRASNOYARSK, SIBERIA. JOURNAL OF CLUSTER SCIENCE, 30, 589-597.
30. BAKER, S., & PERIANOVA, O. V. (2019). BIO-NANOBACTERICIDES: AN EMANATING CLASS OF NANOPARTICLES TOWARDS COMBATING MULTI-DRUG RESISTANT PATHOGENS. SN APPLIED SCIENCES, 1(7), 699
31. SYED, B., PRASAD, M. N., KUMAR, K. M., & SATISH, S. (2018). BIOCONJUGATED NANO-BACTERICIDAL COMPLEX FOR POTENT ACTIVITY AGAINST HUMAN AND PHYTOPATHOGENS WITH CONCERN OF GLOBAL DRUG RESISTANT CRISIS. SCIENCE OF THE TOTAL ENVIRONMENT, 637, 274-281.
32. CUSUMANO, G., FLORES, G. A., VENANZONI, R., & ANGELINI, P. (2025). THE IMPACT OF ANTIBIOTIC THERAPY ON INTESTINAL MICROBIOTA: DYSBIOSIS, ANTIBIOTIC RESISTANCE, AND RESTORATION STRATEGIES. ANTIBIOTICS, 14(4), 371. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14040371
33. GOUVEIA, C., PALOS, C., PEREIRA, P., RAMOS, L. R., & CRAVO, M. (2020). FECAL MICROBIOTA TRANSPLANT IN A PATIENT INFECTED WITH MULTIDRUG-RESISTANT BACTERIA: A CASE REPORT. GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY, 28(1), 56. HTTPS://DOI.ORG/10.1159/000507263
34. CHAVADA, J., MUNESHWAR, K. N., GHULAXE, Y., WANI, M., SARDA, P. P., & HUSE, S. (2023). ANTIBIOTIC RESISTANCE: CHALLENGES AND STRATEGIES IN COMBATING INFECTIONS. CUREUS. CUREUS, INC.

HTTPS://DOI.ORG/10.7759/CUREUS.46013